Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation

Journal of Cardiovascular Pharmacology

Volumn 36, Issue 1, 2000, Pages 77-89

  Fedorov, Vadim V ^a   Sharifov, Oleg F ^a   Beloshapko, Galina G ^a   Yushmanova, Anna V ^a   Rosenshtraukh, Leonid V ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Electrophysiologic mapping; Nibentan; Refractory period; Wavelength

Indexed keywords

ANTIARRHYTHMIC AGENT; NIBENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART EXCITATION; HEART MUSCLE REFRACTORY PERIOD; NONHUMAN; PRIORITY JOURNAL; VAGUS NERVE STIMULATION;

EID: 0033946402     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200007000-00011     Document Type: Article

References (4)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155: 469-73.
2. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-49.
3. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation: an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994;48:345-71.
4. Singh B, Mody FV, Lopez B, Sarma J. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization. Am J Cardiol 1999;84:161R-73R.